Ionis Enters Agreement With Roche For Two Novel RNA-Targeted Programs For Alzheimer's Disease And Huntington's Disease
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has entered into an agreement with Roche for two novel RNA-targeted programs for Alzheimer's and Huntington's diseases. The deal could potentially lead to new treatments for these neurodegenerative diseases.
September 27, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals' partnership with Roche for RNA-targeted programs could potentially lead to new treatments for Alzheimer's and Huntington's diseases, which may positively impact the company's stock.
The partnership with Roche could potentially lead to the development of new treatments for Alzheimer's and Huntington's diseases. If successful, this could significantly increase Ionis Pharmaceuticals' revenues and positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100